Skip to content

PROMINENT Smoking Cessation Study

Discovering the molecular signatures of cancer PROMotion to INform prevENTion (PROMINENT): Smoking Cessation Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN12925323
Enrollment
150
Registered
2024-09-02
Start date
2024-08-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer Cancer

Interventions

Participants will have two study visits - the first one will be at the same time as their lung health check/ clinic appointment, or on a different day if this is more convenient for them and the secon

Sponsors

University of Manchester
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. ALL 1.1. Self-reported current cigarette smoker 1.2. Carbon Monoxide (CO) reading >=5 ppb 1.3. Intends to quit smoking / undertake a smoking quit attempt within 3 months 1.4. No prior history of cancer 1.5. Able to provide informed consent 2. Lung Health Check attendees 2.1. Aged >=55 years 2.2. PLCOM2012 score >=1.51% (or eligible for screening if alternative risk model is used) 3. MFT-CURE attendees 3.1. Aged >=40 years

Exclusion criteria

Exclusion criteria: 1. All 1.1. Never or former smoker (has not smoked within the last 2 weeks) 1.2. Carbon Monoxide (CO) reading <5 ppb 1.3. Prior history of cancer 2. Lung Health Check attendees 2.1. Aged <55 years 2.2. Decline or unable to undertake LDCT screening 3. MFT-CURE attendees 3.1. Aged <40 years

Design outcomes

Primary

MeasureTime frame
Molecular signals measured by molecular signature as observed in mouth and nose samples, at baseline and follow-up (9 – 12 months)

Secondary

MeasureTime frame
There are no secondary outcome measures

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 14, 2026